FDA authorizes protein-based Novavax Covid vaccine for adults

Approval of shot widens options against the virus as CDC will meet next week to decide whether to sign off on vaccine

The Food and Drug Administration (FDA) on Wednesday authorized Novavax's Covid-19 vaccine for emergency use in people 18 years of age or older, widening vaccine options in the US against the virus as the fourth vaccine to get approval by the agency.

The Centers for Disease Control and Prevention (CDC) will meet next week to decide whether to sign off on the vaccine and determine who should get the shot before pharmacies and other healthcare providers can start administering them. Novavax is also expected to finish its quality testing in the next few weeks" before the doses are provided.